SLEEPZ AG — Share Issue/Capital Change 2007

Aug 16, 2007

News Details

Corporate | 16 August 2007 11:00

bmp AG: ‘First Closing’ at Revotar Financing Round

bmp AG / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

The bmp AG (ISIN DE0003304200) notifies that its shareholding of Revotar
Biopharmaceuticals AG successfully concluded within the current financing
round about in total 10-15 million EUR a 'first closing' of 2.88 million
EUR. Besides the lead investor in the first closing, Millhouse Private
Equity Trust, Sydney, also the MVC Unternehmensbeteiligungsgesellschaft
mbH, the Deutsche Life Science GmbH and the bmp AG attended the round.
bmp's shareholding of the company amounts to presently 44.1 % after
implementation of the financing round.

The resources made available within the financing serve to a further
clinical development of the core product of 'Bimosiamose' and to the
construction and extension of the innovative development pipeline of
Revotar.

Mr. Oliver Borrmann, Executive Chairman of the bmp AG: 'The successful
conclusion of the first closing ensures the financing of the Revotar until
early summer of 2008 and allows a further pushing of the current
development projects. This is a good basis for the implementation of the
final closing of the financing round by the end of the year'.

About Revotar Biopharmaceuticals AG:
As a biotechnology company, it researches and develops low-molecular agents
for the treatment of phlogistic diseases as well as psoriasis, acute
pulmonic failure/ acute progressive respiratory distress syndrome of adults
(ALI/ARDS) and COPD (chronical obstructive lung disease). The world-wide
best developed pan selektin antagonist bimosiamose, for which Revotar holds
the exclusive rights, has already passed successfully numerous pre-clinical
animal models as well as the clinical stage I and stage IIa in the
indications asthma and psoriasis.
bmp has participated in the company since July 2000.
For further information: www.revotar-ag.de.

About bmp AG:
As an internationally operating private equity asset manager, bmp (ISIN
DE0003304200) invests own resources directly into company participations
and, at the same time, is engaged as a funds manager for funds of funds and
as a private equity advisor. To its shareholdings, bmp supplies not only
capital, but also 10 years of comprehensive know-how as a business
developer. With the experience from more than 80 own shareholdings, 12
initial public offers, as well as more than 25 trade sales from the
portfolio, bmp is among the most competent venture capital companies in
Germany and Poland.

For further information:

bmp AG
Corinna Riewe
Investor Relations

Schlüterstraße 38
10629 Berlin

Tel: 030-20 30 5-567
Fax: 030-20 30 5- 555
E-mail: criewe@bmp.com
Internet: www.bmp.com

This issue of Corporate News represents neither an offering nor a request
for the tendering of bids for the purchase of securities – particularly not
in the US and not in any countries or jurisdictions in which offers,
requests for the tendering of bids for purchases or for sales would not be
permitted without previous registration or approval in accordance with the
stipulations of the respectively applicable securities regulations.

This issue of Corporate News represents neither an offer for the sale of
individual proprietary shares nor a request for the submission of an offer
for the purchase of individual shares; it is intended solely for
information purposes.
DGAP 16.08.2007

---

Language: English
Issuer: bmp AG
Schlüterstraße 38
10629 Berlin
Deutschland
Phone: +49 (0)30 20 305-0
Fax: +49 (0)30 20 305-532
E-mail: ir@bmp.com
Internet: www.bmp.com
ISIN: DE0003304200
WKN: 330420
Indices:
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin, Stuttgart, München, Hamburg, Düsseldorf; Foreign
Exchange(s) Warschau

End of News DGAP News-Service

---